笔名: Scotty 于October 29, 19115 05:28:39:

I'm happy very good site artane tablets Turnover from Glivec/Gleevec (imatinib), for chronic myeloid leukaemia and gastrointestinal stromal tumours was down 3% at $1.13 billion, while the successor to Glivec, Tasigna (nilotinib), also approved for CML, contributed $315 million, up 21%.

答复此贴